AIM ImmunoTech Inc.

AIM

Healthcare|Biotechnology|US

$0.15

+0.00 (+1.91%)

Tangible Book / Share

$0.35

Cash / Share

$0.58

Next Earnings Report

Nov 16, 2026

EPS est. -$0.09 · Revenue est. $25.7K

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Jun 24, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (2)

Dec 2026

Est. completion

P1P2Metastatic Pancreatic Cancer

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

NCT05927142n=43

Apr 2027

Est. completion

P2Prostate Adenocarcinoma

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

NCT03899987n=12

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2024

P1P2

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

NCT03734692

Recent Press Releases

AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer

Nov 5, 2026 · GlobeNewsWire

AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

Oct 7, 2026 · GlobeNewsWire

AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential

Oct 5, 2026 · GlobeNewsWire

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

Oct 1, 2026 · GlobeNewsWire

AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

Sep 30, 2026 · GlobeNewsWire

AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib

Sep 22, 2026 · GlobeNewsWire

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

Sep 9, 2026 · GlobeNewsWire

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

Sep 2, 2026 · GlobeNewsWire

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

Aug 31, 2026 · GlobeNewsWire

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference

Aug 27, 2026 · GlobeNewsWire

SEC Filings (127)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	8-K	Material event	Document Index
Nov 3, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Sep 30, 2026	ARS	Annual report to holders	Document Index
Sep 30, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Sep 14, 2026	8-K	Material event	Document Index
Sep 10, 2026	8-K	Material event	Document Index
Sep 4, 2026	8-K	Material event	Document Index
Aug 11, 2026	8-K	Material event	Document Index
Aug 10, 2026	8-K	Material event	Document Index
Aug 7, 2026	10-Q	Quarterly report	Document Index
Aug 6, 2026	8-K	Material event	Document Index
Aug 5, 2026	8-K	Material event	Document Index
Jul 16, 2026	8-K	Material event	Document Index
Jul 9, 2026	S-8	Employee stock plan	Document Index
Jun 25, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Jun 24, 2026	424B3	Offering prospectus	Document Index
Jun 23, 2026	EFFECT		Document Index
Jun 18, 2026	424B3	Offering prospectus	Document Index
Jun 18, 2026	S-1	IPO / offering registration	Document Index
Jun 16, 2026	EFFECT		Document Index
Jun 15, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Jun 15, 2026	8-K	Material event	Document Index
Jun 11, 2026	8-K	Material event	Document Index
Jun 10, 2026	8-K	Material event	Document Index
Jun 10, 2026	424B5	Offering prospectus	Document Index
Jun 8, 2026	S-1	IPO / offering registration	Document Index
Jun 4, 2026	8-K	Material event	Document Index
May 27, 2026	SC 13G	Passive 5%+ stake	Document Index
May 21, 2026	8-K	Material event	Document Index
May 21, 2026	424B5	Offering prospectus	Document Index
May 19, 2026	424B5	Offering prospectus	Document Index
May 19, 2026	8-K	Material event	Document Index
May 15, 2026	10-Q	Quarterly report	Document Index
May 14, 2026	8-K	Material event	Document Index
May 12, 2026	SC 13G	Passive 5%+ stake	Document Index
May 12, 2026	8-K	Material event	Document Index
May 8, 2026	8-K	Material event	Document Index
Apr 10, 2026	8-K	Material event	Document Index
Apr 10, 2026	424B5	Offering prospectus	Document Index
Mar 27, 2026	10-K	Annual report	Document Index